Table 5.

Net reclassification improvement for CVD events with the 13 negative risk markers in MESA participants with a pre-test 10-year CVD risk ≥7.5% (N=3,833, including 3,227 participants without events and 606 with events). Reclassification was defined as a post-test risk <7.5%.

	Prevalence of risk marker		Correct reclassification (non-events)		Incorrect reclassification (events)
	N	%	N	%	N	%	NRI
CAC Score = 0	1,291	33.6	710	22.0	50	8.3	13.75
HsCRP < 2 mg/dL	1,923	50.4	118	3.7	12	2.0	1.68
Homocysteine < 10µmol/L	2,252	58.7	87	2.7	8	1.3	1.38
NT-ProBNP < 100pg/mL	1,992	62.5	93	2.9	13	2.2	0.74
No Microalbuminuria	3,294	86.1	52	1.6	4	0.7	0.95
Ankle-Brachial Index > 0.9 – < 1.3	3,079	81.4	100	3.1	10	1.7	1.45
CIMT ≤ 25th Percentile	482	12.7	216	6.7	11	1.8	4.88
No Carotid Plaque	1,747	46.2	211	6.5	13	2.2	4.39
FMD ≥ 5% Change	379	24.0	41	1.3	3	0.5	0.78
No Family History of CHD	1,970	55.4	207	6.4	17	2.8	3.61
No Family History of Premature CHD	2,341	82.0	74	2.3	9	1.5	0.81
No Metabolic Syndrome	2,094	54.6	52	1.6	4	0.7	0.95
Healthy Lifestyle	738	26.6	87	2.7	9	1.45	1.21

CVD indicates cardiovascular disease; NRI, net reclassification improvement; CAC, coronary artery calcium; HsCRP, high sensitivity C-reactive protein; NT-ProBNP, N-terminal pro-brain natriuretic peptide; CIMT, carotid intima-media thickness; FMD, flow mediated dilation; CHD, coronary heart disease.